HC Wainwright Brokers Cut Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – HC Wainwright lowered their FY2026 earnings estimates for Esperion Therapeutics in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn $2.19 per share for the year, down from their prior estimate of $2.50. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2027 earnings at $3.07 EPS and FY2028 earnings at $5.97 EPS.

Several other analysts have also recently issued reports on ESPR. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Esperion Therapeutics in a research report on Tuesday. StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Esperion Therapeutics Price Performance

Shares of ESPR stock traded up $0.10 on Friday, hitting $2.19. The stock had a trading volume of 2,794,894 shares, compared to its average volume of 6,992,384. The company’s 50 day moving average price is $2.30 and its 200-day moving average price is $2.07. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40. The firm has a market capitalization of $414.79 million, a P/E ratio of -0.99 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the prior year, the firm earned ($0.76) EPS.

Institutional Trading of Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC purchased a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at about $29,000. Jacob Asset Management of New York LLC acquired a new stake in shares of Esperion Therapeutics during the third quarter worth about $59,000. Monaco Asset Management SAM grew its holdings in shares of Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 476,477 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Esperion Therapeutics in the 3rd quarter valued at about $131,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 225,767 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.